Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01846442 · ClinicalTrials.gov registry record · Phase 3

Topical DHEA Against Vaginal Atrophy

A Phase 3 study of Vaginal Atrophy, sponsored by EndoCeutics.

Completed
Registry status
Phase 3
Development phase
218
Enrollment target
8
Study locations

NCT01846442: Completed Phase 3 study of Vaginal Atrophy, sponsored by EndoCeutics.

NCT01846442 is a Phase 3 study of Vaginal Atrophy that has completed, run by EndoCeutics. The registered enrollment target is 218 participants, below the 332-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (34% lower). The trial reports 8 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01846442, a Phase 3 study of Vaginal Atrophy, has completed, sponsored by EndoCeutics.

COMPLETED
Registry status
Phase 3
Development phase
218 participants
Enrollment target
8
Study locations

Study Summary

The purpose of this study is to determine the dose-response of vaginal mucosa parameters to the local action of DHEA (Dehydroepiandrosterone) in postmenopausal women suffering from vaginal atrophy.

Primary Outcome

The percentage of parabasal cells was determined from the vaginal smears collected during the study. A 100-cell count was performed by a central laboratory to classify cells as parabasal (P) (including basal), intermediate (I), and superficial (S) squamous cell types. Data obtained at Baseline and Week 12 as well as the change from Baseline to Week 12 are presented.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG DHEA (0.25%)
  • DRUG DHEA (0.5%)
  • DRUG DHEA (1.0%)

Study Locations (8)

Quebec

  • EndoCeutics site # 10 - Montreal
  • EndoCeutics site # 09 - Montreal
  • EndoCeutics site # 08 - Shawinigan
  • EndoCeutics site # 11 - Sherbrooke

Other

  • EndoCeutics site # 02 - Québec
  • EndoCeutics site # 01 - Québec

Ohio

  • EndoCeutics site # 05 - Cleveland

Virginia

  • EndoCeutics site # 03 - Norfolk

Trial Details

FieldValue
Enrollment Target 218 participants
Start Date 2007-06
Est. Completion 2008-10
Phase Phase 3
EndoCeutics

6 total trials

What the finished NCT01846442 record still lists

NCT01846442 is an interventional study that assigns participants to a tested intervention. The registered 218 participants enrollment target is mid-sized for trials with a published cap, below the 332-participant average among 9 other Vaginal Atrophy trials with a reported enrollment target (34% lower).

The record links to 1 condition, with Vaginal Atrophy appearing as the primary indexed condition, and to 4 interventions - of which Placebo is the first listed.

NCT01846442 lists 8 locations in 4 states (Quebec, Other, Ohio).

Frequently Asked Questions

What is clinical trial NCT01846442 about?

NCT01846442 is a clinical study titled "Topical DHEA Against Vaginal Atrophy". The purpose of this study is to determine the dose-response of vaginal mucosa parameters to the local action of DHEA (Dehydroepiandrosterone) in postmenopausal women suffering from vaginal atrophy.

What is the current status of trial NCT01846442?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 218 participants. The study started on 2007-06. Estimated completion is 2008-10.

What conditions does trial NCT01846442 study?

This clinical trial studies the following conditions: Vaginal Atrophy.

What interventions are being tested in trial NCT01846442?

The interventions under investigation include: Placebo (DRUG), DHEA (0.25%) (DRUG), DHEA (0.5%) (DRUG), DHEA (1.0%) (DRUG).

Who is sponsoring clinical trial NCT01846442?

This trial is sponsored by EndoCeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01846442 being conducted?

This trial has 8 study locations across Ohio, Virginia, Quebec. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Vaginal Atrophy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01846442's enrollment target sits among peer trials

218 3rd of 9 higher than 7 of 9 other Vaginal Atrophy trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Vaginal Atrophy trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04693858 · 218 participants · NA

    Efficacy Trial of the CALM Intervention

  • NCT05909202 · 218 participants · NA

    A Nature-Based Virtual Reality (VR) Intervention in Family Caregivers of Allogeneic Hematopoietic Stem Cell Transplant (HSCT) Recipients

  • NCT06000761 · 218 participants · NA

    Frequent Standardized Oral Care Using Human Milk in the Neonatal Intensive Care Unit

  • NCT06249126 · 218 participants · NA

    Primary Subtalar Arthrodesis for Calcaneal Fractures

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01846442, the US trial registry maintained by the National Library of Medicine. NCT01846442 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.